ArticleNeurology. Genetics2026
Proband Nanopore Long-Read Genome Sequencing Facilitates Preimplantation Genetic Testing for Facioscapulohumeral Muscular Dystrophy.
Article in Neurology. Genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanopore Ultra-Long Sequencing for FSHD: From Molecular Diagnosis to Preimplantation Genetic Testing.Genes · 2026Review
- Technological Advances in Molecular Diagnostic Methods for Hereditary Diseases in Preconception and Prenatal Settings.Current issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is caused by contraction of the D4Z4 repeat array at 4q35. Genetic diagnosis is particularly difficult in somatic mosaic cases, where conventional short-read sequencing cannot directly resolve pathogenic haplotypes. We aimed to establish a strategy using Nanopore ultra-long-read sequencing for accurate haplotype resolution and to demonstrate its clinical application in preimplantation genetic testing for monogenic disease (PGT-M). Methods: A male patient with somatic mosaic FSHD1 underwent Nanopore ultra-long-read sequencing to directly span the D4Z4 repeat array, identify contraction events, and distinguish normal and pathogenic haplotypes. Embryos derived from the patient were subsequently screened using this approach combined with short-read sequencing and Sanger sequencing to determine carrier status. Finally, Bionano optical genome mapping (OGM) was performed for prenatal validation. Results: Nanopore sequencing revealed 3 haplotypes with 4, 16, and 33 D4Z4 repeat units on 4qA, consistent with somatic mosaicism. Ultra-long reads enabled direct identification of a pathogenic 4-unit haplotype and precise haplotype phasing despite limited downstream SNPs. Methylation profiling confirmed hypomethylation of the pathogenic allele. Of 8 biopsied embryos, 5 were definitively classified as unaffected, 2 showed upstream recombination within a 224-kb region, and 1 carried the pathogenic haplotype. Integration of Nanopore, short-read sequencing, and Sanger sequencing resolved uncertain cases and reduced misclassification risk. An unaffected embryo was transferred, leading to the birth of a healthy infant. Prenatal OGM confirmed 17 and 33 D4Z4 repeat units without contraction, concordant with preimplantation results. Discussion: Nanopore ultra-long-read sequencing provides accurate detection of D4Z4 repeat contractions and haplotype resolution in somatic mosaic FSHD1, overcoming the limitations of conventional short-read sequencing. Applied to PGT-M, this approach ensured reliable embryo diagnosis and successful prevention of disease transmission. These findings support the broader potential of ultra-long-read sequencing for genetic testing and diagnosis of neurologic disorders involving complex repeat-mediated loci.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.